Back to News
Market Impact: 0.2
Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins
Source: PR Newswire
Healthcare & Biotech
Initial results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson’s disease are being presented at MDS 2026. The trial reported initial safety and tolerability data, with most treatment-emergent adverse events described as mild; no efficacy results or numerical safety data are provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Why is Telix Pharmaceuticals stock rallying today?
- Why is Natera stock sliding today?
- Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD
- ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
- McKesson and CD&R agree to acquire Option Care Health for $5.8 billion
- LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Portfolio Monitoring: Build an Alert Policy Analysts Can Audit
- The Great Divergence: North American Banking at the Crossroads of Monetary Policy and Agentic AI (Q4 2025 Bank Earnings)